KRAS and lung adenocarcinoma: Among KRAS mutations, the glycine‐to‐cysteine substitution at codon 12 (G12C) is the most frequent KRAS substitution in lung adenocarcinoma (LUAD), occurring in approximately 40% of KRAS‐mutant LUAD cases.3